Valeant Pharmaceuticals International (VRX) continues to come under pressure due to an investigation by the U.S. Congress into drug prices. Valeant was the subject of a New York Times article over the weekend entitled "Valeant's Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers."
Valeant Pharmaceuticals International gapped open lower Monday and declined for the majority of the morning. Shares finished with a loss of 18.86 at $163.46 on above average volume. The stock closed near the lower end of a 1-week trading range.
For comments and feedback contact: editorial@rttnews.com
Business News